Probiotics and Prebiotics As a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review

Overview

Journal Foods

Specialty Biotechnology

Date 2021 Aug 27

PMID 34441497

Citations 14

Authors

Valentina Castillo

Fernanda Figueroa

Karoll Gonzalez-Pizarro

Paz Jopia

Claudia Ibacache-Quiroga

Affiliations

Soon will be listed here.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a chronic non-communicable disease, with a prevalence of 25% worldwide. This pathology is a multifactorial illness, and is associated with different risks factors, including hypertension, hyperglycemia, dyslipidemia, and obesity. Beside these predisposing features, NAFLD has been related to changes in the microbiota, which favor the disease progression. In this context, the modulation of the gut microbiota has emerged as a new therapeutic target for the prophylaxis and treatment of NAFLD. This review describes the changes in the gut microbiota associated with NAFLD and the effect of probiotics, prebiotics, and synbiotics on the gut microbiota, liver damage, anthropometric parameters, blood lipids, inflammation markers and insulin resistance in these patients.

Citing Articles

Non-alcoholic fatty liver disease: Dietary and nutraceutical approaches.

Cogorno L, Formisano E, Vignati A, Prigione A, Tramacere A, Borgarelli C Liver Res. 2025; 7(3):216-227.

PMID: 39958388 PMC: 11791914. DOI: 10.1016/j.livres.2023.08.005.

Exert Anti-inflammatory Effects in Hepatic Fibrosis by the Gut-Liver Axis and Enhancing SCFA Metabolism.

Zhang L, Liu Z, Liu Y, Chen Y, Chen J, Lu C J Agric Food Chem. 2025; 73(8):4617-4629.

PMID: 39945558 PMC: 11869285. DOI: 10.1021/acs.jafc.4c07952.

The role of intestinal flora in metabolic dysfunction-associated steatotic liver disease and treatment strategies.

Wang L, Sun J, Chen S, Sun Y, Zheng Y, Feng J Front Med (Lausanne). 2025; 11():1490929.

PMID: 39839647 PMC: 11746088. DOI: 10.3389/fmed.2024.1490929.

Vinpocetine and Lactobacillus improve fatty liver in rats: role of adiponectin and gut microbiome.

El-Baz A, Shata A, Nouh N, Jamil L, Hafez M, Negm S AMB Express. 2024; 14(1):89.

PMID: 39095672 PMC: 11297008. DOI: 10.1186/s13568-024-01731-2.

Prebiotic Treatment in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)-A Randomized Pilot Trial.

Reshef N, Gophna U, Reshef L, Konikoff F, Gabay G, Zornitzki T Nutrients. 2024; 16(11).

PMID: 38892505 PMC: 11174003. DOI: 10.3390/nu16111571.

References

Chen L, Chen Y, Cheng K, Chien T, Chan C, Tsao S . Antiobesity effect of Lactobacillus reuteri 263 associated with energy metabolism remodeling of white adipose tissue in high-energy-diet-fed rats. J Nutr Biochem. 2018; 54:87-94. DOI: 10.1016/j.jnutbio.2017.11.004. View

Armstrong M, Hull D, Guo K, Barton D, Hazlehurst J, Gathercole L . Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol. 2015; 64(2):399-408. PMC: 4713865. DOI: 10.1016/j.jhep.2015.08.038. View

Liang Y, Lin C, Zhang Y, Deng Y, Liu C, Yang Q . Probiotic mixture of Lactobacillus and Bifidobacterium alleviates systemic adiposity and inflammation in non-alcoholic fatty liver disease rats through Gpr109a and the commensal metabolite butyrate. Inflammopharmacology. 2018; 26(4):1051-1055. DOI: 10.1007/s10787-018-0479-8. View

Saez-Lara M, Robles-Sanchez C, Ruiz-Ojeda F, Plaza-Diaz J, Gil A . Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials. Int J Mol Sci. 2016; 17(6). PMC: 4926461. DOI: 10.3390/ijms17060928. View

Chong C, Orr D, Plank L, Vatanen T, OSullivan J, Murphy R . Randomised Double-Blind Placebo-Controlled Trial of Inulin with Metronidazole in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients. 2020; 12(4). PMC: 7230525. DOI: 10.3390/nu12040937. View

Mattia A, Merker R . Regulation of probiotic substances as ingredients in foods: premarket approval or "generally recognized as safe" notification. Clin Infect Dis. 2008; 46 Suppl 2:S115-8. DOI: 10.1086/523329. View

Jasirwan C, Lesmana C, Hasan I, Sulaiman A, Gani R . The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms. Biosci Microbiota Food Health. 2019; 38(3):81-88. PMC: 6663510. DOI: 10.12938/bmfh.18-032. View

Ekhlasi G, Kolahdouz Mohammadi R, Agah S, Zarrati M, Hosseini A, Arabshahi S . Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial. J Res Med Sci. 2017; 21:106. PMC: 5322689. DOI: 10.4103/1735-1995.193178. View

Ruengsomwong S, La-Ongkham O, Jiang J, Wannissorn B, Nakayama J, Nitisinprasert S . Microbial Community of Healthy Thai Vegetarians and Non-Vegetarians, Their Core Gut Microbiota, and Pathogen Risk. J Microbiol Biotechnol. 2016; 26(10):1723-1735. DOI: 10.4014/jmb.1603.03057. View

10.

Chen Y, Lin Y, Lin J, Yang N, Chen M . Sugary Kefir Strain Lactobacillus mali APS1 Ameliorated Hepatic Steatosis by Regulation of SIRT-1/Nrf-2 and Gut Microbiota in Rats. Mol Nutr Food Res. 2018; 62(8):e1700903. DOI: 10.1002/mnfr.201700903. View

11.

Sobhonslidsuk A, Chanprasertyothin S, Pongrujikorn T, Kaewduang P, Promson K, Petraksa S . The Association of Gut Microbiota with Nonalcoholic Steatohepatitis in Thais. Biomed Res Int. 2018; 2018:9340316. PMC: 5842744. DOI: 10.1155/2018/9340316. View

12.

Shabalala S, Dludla P, Mabasa L, Kappo A, Basson A, Pheiffer C . The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling. Biomed Pharmacother. 2020; 131:110785. DOI: 10.1016/j.biopha.2020.110785. View

13.

. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100):1151-1210. PMC: 5605883. DOI: 10.1016/S0140-6736(17)32152-9. View

14.

Hempel S, Newberry S, Ruelaz A, Wang Z, Miles J, Suttorp M . Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep). 2012; (200):1-645. PMC: 4780970. View

15.

Clemente J, Ursell L, Parfrey L, Knight R . The impact of the gut microbiota on human health: an integrative view. Cell. 2012; 148(6):1258-70. PMC: 5050011. DOI: 10.1016/j.cell.2012.01.035. View

16.

Sumida Y, Yoneda M . Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2017; 53(3):362-376. PMC: 5847174. DOI: 10.1007/s00535-017-1415-1. View

17.

Reimer R, Maurer A, Eller L, Hallam M, Shaykhutdinov R, Vogel H . Satiety hormone and metabolomic response to an intermittent high energy diet differs in rats consuming long-term diets high in protein or prebiotic fiber. J Proteome Res. 2012; 11(8):4065-74. PMC: 3411197. DOI: 10.1021/pr300487s. View

18.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

19.

Liang Y, Liang S, Zhang Y, Deng Y, He Y, Chen Y . Oral Administration of Compound Probiotics Ameliorates HFD-Induced Gut Microbe Dysbiosis and Chronic Metabolic Inflammation via the G Protein-Coupled Receptor 43 in Non-alcoholic Fatty Liver Disease Rats. Probiotics Antimicrob Proteins. 2018; 11(1):175-185. DOI: 10.1007/s12602-017-9378-3. View

20.

Doron S, Snydman D . Risk and safety of probiotics. Clin Infect Dis. 2015; 60 Suppl 2:S129-34. PMC: 4490230. DOI: 10.1093/cid/civ085. View